SEARCH RESULT

Total Matching Records found : 2687

Indian pharma's generic challenge-DG Shah

-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...

More »

Armed with whistle-blower policy, Ranbaxy to look ahead-Sushmi Dey

-The Business Standard Patient safety & quality our guidance now, says Sawhney Trouble-hit Ranbaxy Laboratories has introduced a whistle-blower policy within the company to encourage transparency and address concerns internally, so that bigger problems could be averted. In his first interaction with the media (the first part of which was published on Sunday) since the drug maker pleaded guilty of making fraudulent statements to the US Food and Drugs Administration (FDA) under its...

More »

Growth falters as UPA completes 4-years in office -Surojit Gupta

-The Times of India NEW DELHI: The second tenure of the UPA coalition has witnessed a sharp slowdown in growth, stubborn prices, high interest rates and faltering business confidence. While there are some tentative signs of a revival on the horizon, the Indian economy is still not out of the woods and experts say sustained policy and governance reforms are needed to lift Asia's third-largest economy back to its potential growth rate...

More »

How GDP understates economic growth-Bill Gates

-The Guardian GDP may be an inaccurate indicator in sub-Saharan Africa, which is a concern for those who want to use statistics to help the world's poorest people Even in good financial times, development aid budgets are hardly overflowing. Government leaders and donors must make hard decisions about where to focus their limited resources. How do you decide which countries should get low-cost loans or cheaper vaccines, and which can afford to...

More »

Arvind Panagariya, a professor of Indian economics at Columbia University interviewed by Ullekh NP

-The Economic Times Arvind Panagariya, a professor of Indian economics at Columbia University, hits out at Nobel laureate and Harvard University professor Amartya Sen over his call to confront MPs with the "number of deaths" a delayed Food Security Bill can cause. The former chief economist at the Asian Development Bank counters Sen's argument that it is high social spending that has contributed to the economic growth of Asian economies such...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close